Education
About Us
Working with TipRanks
Follow Us
Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
BGT Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume38.03K
Average Volume (3M)988.87K
Market Cap
AU$9.46M
Enterprise ValueAU$8.37M
Total Cash (Recent Filing)AU$1.14M
Total Debt (Recent Filing)AU$51.21K
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding305,061,100
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtA near-zero debt load materially reduces insolvency and interest-rate risk, giving management more financial flexibility. For a cash-burning development-stage biotech, low leverage preserves runway options, easing the need for onerous debt financing and supporting longer-term R&D plans.
Signs Of Cash-flow ImprovementImproved free cash flow in 2025 and an earlier year of positive OCF indicate the company can achieve episodic operational improvements. These signs suggest cost control or milestone-driven receipts that, if repeatable, lower near-term funding needs and improve planning visibility over the next several quarters.
Stabilized Loss TrajectoryThe company’s losses have not meaningfully accelerated, implying management may be stabilizing operating spend or pacing development activity. A steadier loss profile reduces downside volatility, making fundraising and project prioritization more manageable over a multimonth horizon.
Bears Say
Revenue Collapsed To Near-zeroRevenue falling to essentially zero removes a durable commercial foundation, extending reliance on external funding. Without recurring sales, the company faces a longer timeline to monetize its pipeline, increasing execution risk and the probability of dilution or strategic pivots to remain solvent.
Persistent Cash BurnSustained negative OCF and FCF across multiple years indicate ongoing cash consumption that outpaces internal generation. Persistent burn necessitates recurrent fundraising, which can dilute shareholders, distract management, and constrain long-term R&D investments unless a durable improvement in cash generation occurs.
Eroding Equity / Shrinking Net WorthMaterial declines in shareholders' equity reflect cumulative operating losses and weaken the balance sheet's capacity to absorb setbacks. A shrinking net worth limits borrowing capacity, reduces strategic optionality, and signals that continued losses could undermine long-term solvency without external capital.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$9.46M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Aug 25, 2025. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 305,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.48%
Trailing 12-Months
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---